Latest & greatest articles for metformin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on metformin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on metformin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for metformin

81. Toxicokinetics of Metformin During Hemodialysis Full Text available with Trip Pro

Toxicokinetics of Metformin During Hemodialysis 29318220 2018 11 13 2468-0249 2 4 2017 Jul Kidney international reports Kidney Int Rep Toxicokinetics of Metformin During Hemodialysis. 759-762 10.1016/j.ekir.2017.02.017 Ayoub Paul P Biochemistry Department, University of Montreal Health Center, University of Montreal, Montreal, Quebec, Canada. Hétu Pierre-Olivier PO Department of Nephrology, Verdun Hospital, University of Montreal, Montreal, Quebec, Canada. Cormier Monique M Department

2017 Kidney international reports

82. Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control. Full Text available with Trip Pro

Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control. To evaluate the effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus (T2DM) and inadequate glycemic control.A randomized, double-blind, placebo-controlled clinical trial was carried out on 12 patients with T2DM and inadequate glycemic control [glycated hemoglobin A1c (A1C) ≥ 7%] with metformin as monotherapy (≥ 1500 mg per day) for at least (...) the previous 90 days. Fasting and postprandial glucose were measured before and after the pharmacological intervention. A1C, lipid profile, creatinine and uric acid were also evaluated. After randomization, all patients continued with their dose of metformin. Six subjects received placebo and the other six volunteers took diacerein. Data were tested using the Wilcoxon signed-rank, Mann-Whitney U and chi-square tests. The Institutional Ethics Committee approved the study protocol.After 90 days of diacerein

2017 Archives of endocrinology and metabolism Controlled trial quality: uncertain

83. Which patients with metabolic syndrome benefit from metformin?

Which patients with metabolic syndrome benefit from metformin? Which patients with metabolic syndrome benefit from metformin? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Which patients with metabolic syndrome benefit from metformin? View/ Open Date 2016-11 Format Metadata Abstract Q Which patients with metabolic (...) syndrome benefit from metformin? Evidence-based answer: Patients at highest risk for progression to diabetes benefit from metformin. In patients with metabolic syndrome who are in the highest-risk quartile for progression to diabetes (predicted mean 3-year risk, 60%), metformin, 850 mg twice daily, reduces the absolute risk by about 20% over a 3-year period. Metformin doesn't reduce the incidence in patients at lower risk of progression (strength of recommendation [SOR]: C, post-hoc analysis

2017 Clinical Inquiries

84. [Saxagliptin / metformin - benefit assessment according to õ 35a Social Code Book V]

[Saxagliptin / metformin - benefit assessment according to õ 35a Social Code Book V] Saxagliptin/Metformin (Diabetes mellitus Typ 2): Nutzenbewertung gemäß § 35a SGB V (Ablauf Befristung); Dossierbewertung; Auftrag A16-4 [Saxagliptin / metformin - benefit assessment according to § 35a Social Code Book V] Saxagliptin/Metformin (Diabetes mellitus Typ 2): Nutzenbewertung gemäß § 35a SGB V (Ablauf Befristung); Dossierbewertung; Auftrag A16-4 [Saxagliptin / metformin - benefit assessment according (...) to § 35a Social Code Book V] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Saxagliptin/Metformin (Diabetes mellitus Typ 2): Nutzenbewertung gemäß § 35a SGB V (Ablauf Befristung); Dossierbewertung

2017 Health Technology Assessment (HTA) Database.

85. [Sitagliptin/metformin - benefit assessment according to õ35a Social Code Book V]

[Sitagliptin/metformin - benefit assessment according to õ35a Social Code Book V] Sitagliptin/Metformin (Diabetes mellitus Typ 2): nutzenbewertung gemäß § 35a SGB V (ablauf befristung); dossierbewertung; auftrag A16-45 [Sitagliptin/metformin - benefit assessment according to §35a Social Code Book V] Sitagliptin/Metformin (Diabetes mellitus Typ 2): nutzenbewertung gemäß § 35a SGB V (ablauf befristung); dossierbewertung; auftrag A16-45 [Sitagliptin/metformin - benefit assessment according to §35a (...) Social Code Book V] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Sitagliptin/Metformin (Diabetes mellitus Typ 2): nutzenbewertung gemäß § 35a SGB V (ablauf befristung); dossierbewertung; auftrag

2017 Health Technology Assessment (HTA) Database.

86. Empagliflozin/metformin - benefit assessment

Empagliflozin/metformin - benefit assessment Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Empagliflozin/Metformin – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 30 May 2016). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A16-13 Empagliflozin/metformin – Benefit assessment according to §35a (...) Social Code Book V 1 Extract of dossier assessment A16-13 Version 1.0 Empagliflozin/metformin – Benefit assessment acc. to §35a SGB V 30 May 2016 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Empagliflozin/metformin – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 29 February 2016 Internal Commission No.: A16-13

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

87. Metformin Use in Patients With Historical Contraindications Full Text available with Trip Pro

Metformin Use in Patients With Historical Contraindications 28055052 2017 12 08 2018 12 02 1539-3704 166 3 2017 02 07 Annals of internal medicine Ann. Intern. Med. Metformin Use in Patients With Historical Contraindications. 225-226 10.7326/M16-2712 Lipska Kasia J KJ From Yale School of Medicine, New Haven, Connecticut. eng K23 AG048359 AG NIA NIH HHS United States L30 AG045923 AG NIA NIH HHS United States P30 AG021342 AG NIA NIH HHS United States Journal Article Research Support, N.I.H (...) ., Extramural Comment 2017 01 03 United States Ann Intern Med 0372351 0003-4819 0 Hypoglycemic Agents 9100L32L2N Metformin AIM IM Ann Intern Med. 2017 Feb 7;166(3):191-200 28055049 Contraindications Diabetes Mellitus, Type 2 Humans Hypoglycemic Agents Metformin 2017 1 6 6 0 2017 12 9 6 0 2017 1 6 6 0 ppublish 28055052 2595890 10.7326/M16-2712 PMC5334793 NIHMS850043 N Engl J Med. 1998 Jan 22;338(4):265-6 9441244 Ann Intern Med. 2011 May 3;154(9):602-13 21403054 Lancet. 1998 Sep 12;352(9131):854-65 9742977

2017 Annals of Internal Medicine

88. Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline.

Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline. Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline. | National Guideline Clearinghouse success fail JUN 09 2017 2018 2019 14 Apr 2018 - 12 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving (...) of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline. Practice Committee of the American Society for Reproductive Medicine. Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline. Fertil Steril. 2017 Sep;108(3):426-41. [80 references] This is the current release of the guideline. This guideline meets NGC's 2013 (revised) inclusion criteria. Age Group UMLS Concepts ICD9CM (628.9), (256.4) MSH

2017 National Guideline Clearinghouse (partial archive)

90. Saxagliptin/metformin (type 2 diabetes) - Benefit assessment according to §35a Social Code Book V

Saxagliptin/metformin (type 2 diabetes) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Saxagliptin/Metformin (Diabetes mellitus Typ 2) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 25 October 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports (...) – Commission No. A17-33 Saxagliptin/metformin (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-33 Version 1.0 Saxagliptin/metformin (type 2 diabetes mellitus) 25 October 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Saxagliptin/metformin (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

91. Role of metformin for ovulation induction in infertile patients with PCOS

Role of metformin for ovulation induction in infertile patients with PCOS Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline Practice Committee of the American Society for Reproductive Medicine American Society for Reproductive Medicine, Birmingham, Alabama Metforminalonecomparedwithplaceboincreasestheovulationrateinwomenwithpolycysticovarysyndrome(PCOS)butshouldnot be used as?rst-line therapy for anovulation because oral ovulation (...) induction agents such as clomiphene citrate or letrozole alone are muchmoreeffectiveinincreasingovulation,pregnancy,andlive-birthratesinwomenwithPCOS.Thereisfairevidencethatmetformin alone does not increase rates of miscarriage when stopped at the initiation of pregnancy and insuf?cient evidence that metformin in combinationwithotheragentsusedtoinduceovulationincreaseslive-birthrates.(FertilSteril 2017;108:426–41.2017byAmerican Society for Reproductive Medicine.) Discuss: You can discuss this article

2017 Society for Assisted Reproductive Technology

92. Metformin Use in Patients with Historical Contraindications or Precautions

Metformin Use in Patients with Historical Contraindications or Precautions 4 Department of Veterans Affairs Health Services Research & Development Service Evidence-based Synthesis Program Metformin Use in Patients with Contraindications or Precautions September 2016 Prepared for: Department of Veterans Affairs Veterans Health Administration Quality Enhancement Research Initiative Health Services Research & Development Service Washington, DC 20420 Prepared by: Evidence-based Synthesis Program (...) Affairs and should not be distributed outside the agency. Metformin Use in Patients with Contraindications or Precautions Evidence-based Synthesis Program i PREFACE The VA Evidence-based Synthesis Program (ESP) was established in 2007 to provide timely and accurate syntheses of targeted healthcare topics of particular importance to clinicians, managers, and policymakers as they work to improve the health and healthcare of Veterans. QUERI provides funding for four ESP Centers, and each Center has

2017 Veterans Affairs Evidence-based Synthesis Program Reports

93. Metformin decreases progerin expression and alleviates pathological defects of Hutchinson–Gilford progeria syndrome cells Full Text available with Trip Pro

Metformin decreases progerin expression and alleviates pathological defects of Hutchinson–Gilford progeria syndrome cells Hutchinson-Gilford progeria syndrome (HGPS) is a rare genetic disorder that causes systemic accelerated aging in children. This syndrome is due to a mutation in the LMNA gene that leads to the production of a truncated and toxic form of lamin A called progerin. Because the balance between the A-type lamins is controlled by the RNA-binding protein SRSF1, we have (...) hypothesized that its inhibition may have therapeutic effects for HGPS. For this purpose, we evaluated the antidiabetic drug metformin and demonstrated that 48 h treatment with 5 mmol/l metformin decreases SRSF1 and progerin expression in mesenchymal stem cells derived from HGPS induced pluripotent stem cells (HGPS MSCs). The effect of metformin on progerin was then confirmed in several in vitro models of HGPS, i.e., human primary HGPS fibroblasts, LmnaG609G/G609G mouse fibroblasts and healthy MSCs

2016 NPJ aging and mechanisms of disease

94. [Empagliflozin/metformin]

[Empagliflozin/metformin] Empagliflozin/metformin (diabetes mellitus Typ 2): addendum zum auftrag A16-13; auftrag A16-47 [Empagliflozin/metformin - addendum to commission A16-13] Empagliflozin/metformin (diabetes mellitus Typ 2): addendum zum auftrag A16-13; auftrag A16-47 [Empagliflozin/metformin - addendum to commission A16-13] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Record Status This is a bibliographic record of a published health technology assessment from (...) a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Empagliflozin/metformin (diabetes mellitus Typ 2): addendum zum auftrag A16-13; auftrag A16-47. [Empagliflozin/metformin - addendum to commission A16-13] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 418. 2016 Final publication URL Indexing Status Subject indexing

2016 Health Technology Assessment (HTA) Database.

95. Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study) Full Text available with Trip Pro

Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study) Gemigliptin is a new dipeptidyl peptidase-IV inhibitor. We investigated the efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes (T2D).A total of 433 T2D patients (...) with a glycosylated haemoglobin (HbA1c) level of 7.5% to 11.0% and a fasting plasma glucose (FPG) concentration <270 mg/dL were randomly assigned to 3 groups: (1) gemigliptin 50 mg qd + metformin 1000 to 2000 mg qd (titrated individually), (2) gemigliptin 50 mg qd, or (3) metformin 1000 to 2000 mg qd. The primary end-point was the change in HbA1c level after 24 weeks. Secondary end-points were the changes in FPG, insulin, proinsulin and C-peptide levels. The percentages of responders who achieved an HbA1c level

2016 EvidenceUpdates

96. Metformin Use in Patients with Historical Contraindications or Precautions

Metformin Use in Patients with Historical Contraindications or Precautions Management Briefs eBrief-no116 -- Enter search terms Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Management Briefs eBrief-no116 -- Health Services Research & Development Management eBrief no. 116 » Issue 116 October 2016 The report is a product of the VA/HSR&D Evidence Synthesis Program. Metformin Use in Patients with Historical (...) Contraindications or Precautions Metformin is an oral hypoglycemic medication used primarily for treating type 2 diabetes mellitus. Evidence suggests that in addition to improving glycemic control, metformin may be associated with improved all-cause and cardiovascular mortality and decreased risk of some cancers. However, clinicians have traditionally been advised by the U.S. Food and Drug Administration (FDA) to exercise caution in prescribing metformin to individuals with chronic kidney disease (CKD

2016 Veterans Affairs - R&D

97. Use of metformin to treat diabetes now expanded to patients with moderately reduced kidney function

Use of metformin to treat diabetes now expanded to patients with moderately reduced kidney function Use of metformin to treat diabetes now expanded to patients with moderately reduced kidney function | European Medicines Agency Search Search Menu Use of metformin to treat diabetes now expanded to patients with moderately reduced kidney function Press release 14/10/2016 Recommendations for patients with kidney impairment updated in The European Medicines Agency (EMA) has concluded that metformin (...) -containing medicines can now be used in patients with moderately reduced kidney function (GFR [glomerular filtration rate]=30–59 ml/min) for the treatment of type 2 diabetes. The for these medicines will be updated to revise the current contraindication and give information about doses, monitoring and precautions in patients with reduced kidney function. The recommendations are the result of a review by EMA of metformin-containing medicines following concerns that current scientific evidence does

2016 European Medicines Agency - EPARs

98. Does metformin reduce excess birthweight in offspring of obese pregnant women? A randomised controlled trial of efficacy, exploration of mechanisms and evaluation of other pregnancy complications Full Text available with Trip Pro

Does metformin reduce excess birthweight in offspring of obese pregnant women? A randomised controlled trial of efficacy, exploration of mechanisms and evaluation of other pregnancy complications Does metformin reduce excess birthweight in offspring of obese pregnant women? A randomised controlled trial of efficacy, exploration of mechanisms and evaluation of other pregnancy complications Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found (...) Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Metformin taken by obese pregnant women did not reduce their baby's birthweight. {{author}} {{($index , , , , , , , , , , , , , , , , , , , , , & . Carolyn A Chiswick 1 , Rebecca M Reynolds 2 , Fiona C Denison 1 , Amanda J

2016 NIHR HTA programme

99. Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION) (Abstract)

Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION) To compare the efficacy and safety of combination of vildagliptin and metformin therapy with metformin uptitration in Chinese patients with type 2 diabetes (T2DM) inadequately controlled with low-dose metformin.In this 24-week prospective (...) , randomized, multicentre, open-label study, patients with T2DM inadequately controlled with metformin ≤1000 mg daily were divided 1 : 1 : 1 : 1 into four prespecified subgroups based on age and body mass index (BMI). Patients in each subgroup were randomized 5 : 1 to receive either vildagliptin (50 mg twice daily) plus metformin [500 mg twice daily; vildagliptin and low-dose metformin (VLDM) group] or metformin uptitration [1000 mg twice daily; high-dose metformin (HDM) group]. The primary endpoint

2016 EvidenceUpdates Controlled trial quality: uncertain

100. [Empagliflozin/metformin: benefit assessment according to õ35a Social Code Book V]

[Empagliflozin/metformin: benefit assessment according to õ35a Social Code Book V] Empagliflozin/Metformin: nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A16-1 [Empagliflozin/metformin: benefit assessment according to §35a Social Code Book V] Empagliflozin/Metformin: nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A16-1 [Empagliflozin/metformin: benefit assessment according to §35a Social Code Book V] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (...) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Empagliflozin/Metformin: nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A16-1. [Empagliflozin/metformin: benefit assessment according to §35a Social Code Book V] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit

2016 Health Technology Assessment (HTA) Database.